The optimal management of anti-drug antibodies to infliximab and identification of anti-drug antibody values for clinical outcomes in patients with inflammatory bowel disease
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Colorectal Disease"
DOI: 10.1007/s00384-021-03855-4
Abstract: Secondary loss of response (LOR) to infliximab (IFX) commonly occurs. One cause is the development of anti-drug antibodies (ADAs). Evidence regarding the optimal management of ADAs is lacking. We aim to identify the best practice… read more here.
Keywords: clinical outcomes; ifx; value; management ... See more keywords
Population Pharmacokinetics Analysis of Infliximab in up to 10-Year-Old Patients with Paediatric Inflammatory Bowel Disease: Label-Recommended Dose Fails to Achieve Therapeutic Target Concentration.
Sign Up to like & getrecommendations! Published in 2025 at "Clinical pharmacokinetics"
DOI: 10.1007/s40262-025-01565-6
Abstract: Younger patients with paediatric inflammatory bowel disease (IBD) may require higher infliximab (IFX) doses to attain similar target trough levels compared with older paediatric and adult patients with IBD. This study aimed to investigate the… read more here.
Keywords: ifx; population; bowel disease; paediatric patients ... See more keywords
OP61 Cost-Utility Analyses Of Biologics For Refractory Ulcerative Colitis
Sign Up to like & getrecommendations! Published in 2017 at "International Journal of Technology Assessment in Health Care"
DOI: 10.1017/s0266462317001465
Abstract: INTRODUCTION: Although many biologics (Bs) have been approved for the treatment of moderate-to-severe Ulcerative Colitis (UC) in patients who have responded inadequately to conventional therapy, the selection of Bs is controversial due to the lack… read more here.
Keywords: ifx; treatment; percent; cost ... See more keywords
Monocytes from infliximab-resistant patients with Crohn’s disease exhibit a disordered cytokine profile
Sign Up to like & getrecommendations! Published in 2020 at "Scientific Reports"
DOI: 10.1038/s41598-020-68993-1
Abstract: Crohn's disease (CD) is a chronic inflammatory disorder characterized by immune response dysregulation. Tumor necrosis factor-α (TNFα) is a key cytokine in the pathogenesis of CD, as indicated by the efficacy of anti-TNF-α therapy with… read more here.
Keywords: ifx; cytokine profile; non responders; crohn disease ... See more keywords
Comparison of endoscopic healing and durability between combination therapy with infliximab and azathioprine versus infliximab monotherapy in pediatric Crohn’s disease
Sign Up to like & getrecommendations! Published in 2025 at "Scientific Reports"
DOI: 10.1038/s41598-025-06445-4
Abstract: This retrospective observational study evaluated the effectiveness of endoscopic healing (EH) and the durability of infliximab (IFX) in combination with azathioprine (AZA) versus IFX monotherapy in pediatric patients with Crohn’s disease (CD). EH was assessed… read more here.
Keywords: combination therapy; therapy; combination; ifx ... See more keywords
P295 Comparative Assessment of Infliximab Trough Levels between Point-of-Care Testing and current Standard of Care (enzyme linked immunosorbent assay) in patients with Inflammatory Bowel Disease
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjab076.419
Abstract: Infliximab (IFX) is a monoclonal antibody that targets cytokine tumor necrosis factor; it is used for the treatment of patients with active inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC). IFX… read more here.
Keywords: care; inflammatory bowel; trough levels; ifx ... See more keywords
P384 Therapeutic drug monitoring: performance of the first lateral flow-based Point of Care test for the quantification of infliximab in a finger prick
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjab076.508
Abstract: Promonitor Quick IFX is a lateral flow test (LFT) for the quantification of infliximab (IFX) in human whole blood (finger prick or venous) or serum in 20 minutes. This LFT is based on a sandwich… read more here.
Keywords: performance; test; finger prick; ifx ... See more keywords
P516 Subcutaneous infliximab cut-off points in a large cohort of Spanish patients with inflammatory bowel disease and factors associated with long-term outcomes
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjad212.0646
Abstract: Evidence suggests that subcutaneous formulation of biosimilar infliximab (CT-P13) (SC-IFX) is capable to maintain clinical remission safely and to increase drug levels with a good acceptance in patients with Crohn’s disease (CD) and ulcerative colitis… read more here.
Keywords: week; disease; long term; ifx ... See more keywords
P857 Effectiveness and safety of subcutaneous infliximab in perianal Crohn's disease: a multicentre cohort study
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjad212.0987
Abstract: Infliximab (IFX) demonstrated its effectiveness in perianal CD (pCD) and represents the first-line medical treatment. A subcutaneous (SC) formulation has recently been developed, however so far it has not been specifically investigated in pCD. The… read more here.
Keywords: ifx; pcd; group; remission ... See more keywords
P1058 Safety and effectiveness of subcutaneous infliximab formulation in difficult-to-treat Crohn’s Disease patients with previous exposure to intravenous infliximab: A case-series
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjad212.1188
Abstract: Despite the increased therapeutic armamentarium for Crohn’s Disease (CD), a relevant proportion of patients fail to respond to multiple therapies and ultimately require surgery. Intravenous (IV) infliximab (IFX) reinduction after a drug holiday is associated… read more here.
Keywords: formulation; disease; crohn disease; ifx ... See more keywords
P0586 Nationwide population-based cohort study on the use and persistence of infliximab (IV and SC) in France: the Riposte IBD study
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjae190.0760
Abstract: Subcutaneous infliximab (IFX-SC) is available in France since 2021. Beyond the pivotal trials, real-life data is needed. The aim of the RIPOSTE study is to evaluate the real-life use of IFX-SC in France at a… read more here.
Keywords: initiation group; ifx; group; infliximab ... See more keywords